follows: the final concentration of dNTPs and primers in the reaction mixture was 200 µM and 1 µM respectively. Taq DNA polymerase (Takara, Otsu, Japan) was added to the mixture at a final concentration of 0.05 U µl -1 and the reaction was carried out in Takara Thermal Cycler MP (Takara). The PCR condition was as follows: for glyceraldehyde phosphate dehydrogenase (GAPDH) amplification, 94°C for 3 min and then 94°C for 1 min, 55°C for 1.5 min, 72°C for 2.5 min for 20 cycles and an extension of 72°C for 4 min; for CK20 amplification from cultured cells or oral SCC tissues, 94°C for 3 min and then 94°C for 1 min, 60°C for 1.5 min, 72°C for 2.5 min for 40 cycles and an extension of 72°C for 4 min. For CK20 amplification from blood samples, two-round PCR was used. The conditions were as follows: 94°C for 3 min and then 94°C for 1 min, 65°C for 1.5 min, 72°C for 2.5 min for 30 cycles and an extension of 72°C for 4 min, and then 1 µl aliquots of firstround PCR products were subjected to the second amplification using the same primers and the same conditions. The primers used were: CK20-UP, 5′-CAGACACACGGTGAACTA-3′ (Burchill et al, 1995a) , for CK20-DN, 5′-GATCAGCTTCCACTGTTAGAC-3′ (Buchill et al, 1995a) for CK20 amplification; GAPDH-UP, 5′-GAAATCCCATCACCATCTTCCAGG-3′, and GAPDH-DN, 5′-CATGTGGGCCATGAGGTCCACCAC-3′ for GAPDH amplification.
Cell spiking
HNt cells (10-1000) were added to 5 ml of whole blood samples from a healthy male volunteer, total RNA was extracted from the cell-spiked blood samples, and RT-PCR for CK20 mRNA was performed.
Southern blot analysis
RT-PCR products were separated on 1% agarose gels and Southern blot analysis was carried out by the standard method. The probe used was a digoxigenin-labelled oligonucleotide probe CK20-PR (5′-ATACTTCAGTCTGAAGTCCTCAGCAGCCAG-3′), the sequence of which lay between a pair of amplifying primers CK20-UP and CK20-DN.
Ethical standards
This study has been approved by the ethical committee of Tokushima University School of Dentistry. The patients gave their informed consent before their inclusion in this study.
RESULTS

Site of origin and clinical details of oral SCC patients
The clinicopathological details of the patients are shown in Table  1 . Twelve blood samples from P1 to P12, and seven fresh cancer samples from P4, P6, P12 and P13-P16 were available.
RT-PCR detection of CK20 mRNA in human oral SCC cells and human oral SCC tissues
RT-PCR for CK20 mRNA generated a 370-bp band on agarose gel, but some non-specific extra bands appeared on TYS and HNt cells (Figure 1 ). Southern blot analysis revealed that only a 370-bp band was hybridized with the CK20 specific probe (data not shown). CK20 mRNA was expressed in all of the oral SCC cells (HN, BHY, HNt, IH), one of the salivary adenosquamous cancer cells (TYS), placental tissue and gingival epithelial cells (GE), but not in peripheral blood cells collected from a healthy man (NB) and gingival fibroblasts (GF) ( Figure 1A ). Moreover, CK20 mRNA was expressed in all of the oral SCC tissues ( Figure 1B ). Although CK20 fragments could be amplified by 25-30 cycles with 55°C annealing temperature, some extra bands appeared on the gel. Therefore, we used the condition described in the Materials and methods section (40 cycles with 60°C annealing temperature) to obtain the clear band. GAPDH as an internal control was amplified in all of the samples tested ( Figure 1 ). No amplification was observed in water control samples (B) (Figure 1 ).
Control blood analysis and cell spiking
In 17 control blood samples collected from 14 healthy volunteers and three patients with inflammatory lesions of the oral mucosa, CK20 mRNA was not amplified after two rounds of PCR, however GAPDH mRNA was clearly amplified in all of the blood samples after one round of PCR (data not shown). To test the sensitivity of the technique to detect circulating cancer cells in peripheral blood, a cell spiking experiment was performed. We could detect down to 1 × 10 2 HNt cells diluted in 5 ml of whole human blood collected from a healthy man (Figure 2 ). The 370-bp band on agarose gel electrophoresis was confirmed as the CK20 fragment by Southern blot analysis (data not shown). Southern blot analysis did not increase the sensitivity of the assay, but increased the specificity (data not shown). In this PCR reaction, we also used high annealing temperature (65°C) and high cycle numbers (30 plus 30 cycles) to clearly amplify the specific band and to diminish the extra bands. Nested-PCR may be more suitable to amplify such a small amount of mRNA specifically, however we obtained the specific band only in the cell spiking samples but not in the control samples by this method and the band was confirmed as the CK20 fragment by Southern blot analysis. We, HNt cells (10-1000) were added to 5 ml of whole blood samples from a healthy male volunteer, total RNA was extracted from the cell-spiked blood samples, and 5 µg of total RNA was subjected to RT-PCR. 10 1 , 10 2 , 10 3 : HNt cell number which was added to the blood samples. Molecular weight markers (2878, 1026, 608 bp) were loaded on the first lane therefore, believed that our technique used in this experiment detected the CK20 mRNA as specifically as nested-PCR did.
Detection of CK20 mRNA in the blood samples collected from oral SCC patients
Contrary to our expectation, we detected CK20 mRNA in 11 out of 12 oral SCC patients, including eight primary cancer patients and three recurrent patients in their peripheral blood samples ( Figure  3 ). However, there is no clear relationship between the haematogenous CK20 mRNA and cancer metastasis of oral SCC patients. Only one recurrent patient (P6) who had multiple but early invasive SCC on the mandibular gingiva showed negative results for CK20 mRNA amplification in her peripheral blood sample (Figure 3) . GAPDH was clearly amplified in all of the samples tested, and no amplification was observed in water control samples (Figure 3 ). We examined tumour-free survivors (P2, P4, P5, P7, P8 and P9) for CK20 mRNA again in their peripheral blood, 3-16 months after initial treatment (radiation, chemotherapy and operation). All of the patients tested showed negative RT-PCR results for CK20 mRNA (data not shown). We repeated all of the experiments at least three times, and obtained the same results.
DISCUSSION
Most of the oral SCC cells showed muscular invasion, bone invasion and vascular invasion (lymphatic channels and microvessels) at very early stage. We sometimes observed intravascular tumour embolus on the biopsy materials obtained from oral SCC patients. These observations suggest that oral SCC cells may easily intravasate into the circulation. In fact, we have detected CK20 mRNA in peripheral blood samples collected from 11 out of 12 cases of oral SCC patients as evidence for the existence of cancer cells in the circulation. Several groups have reported use of the RT-PCR method to detect prostatic cancer cells (Fadlon et al, 1996; Henke et al, 1997; Melchior et al, 1997) , melanoma cell (Foss et al, 1995) , and neuroblastoma cells (Burchill et al, 1995b) in peripheral blood by amplifying prostatic specific antigen, tyrosinase and tyrosine hydroxylase respectively. Some investigators used the epithelium-specific cytokeratin (CK8, CK19 or CK20) as a marker for detecting epithelial cancer cells which did not have any specific markers (Burchill et al, 1995a; Krismann et al, 1995; Soeth et al, 1996) . However, Burchill et al (1995a) and Krisman et al (1995) reported that CK8 and CK19 were amplified in a high proportion of normal peripheral blood samples, but CK20 was not amplified in any normal blood samples. In contrast, Moll et al (1992) reported that oral mucosa and oral SCC rarely expressed CK20 protein when examined by immunohistochemistry. However, we detected CK20 mRNA in all of the oral SCC tissues as well as oral SCC-derived cell lines tested when examined by RT-PCR and Southern blotting. These discrepancies may be due to the different sensitivity of the method used. Therefore, we decided to use the CK20 mRNA as a marker for oral SCC cells in this experiment. CK20 mRNA was not amplified in the peripheral blood samples collected from healthy volunteers and was detected only in oral SCC patients when we eliminated a contamination of the blood samples with skin fragments as carefully as possible. However, there was no clear relationship between the detection of haematogenous CK20 mRNA and cancer metastasis of the patients. These results suggest that oral SCC cells may easily intravasate and the intravasation of cancer cells was not critical step for metastasis formation of oral SCC, but extravasation or ectopic growth potential of oral SCC cells may be more important for their metastasis formation. We examined CK20 mRNA in oral SCC patients 3-16 months after initial treatment, all of the tumour-free survivors tested showed negative RT-PCR results for CK20 mRNA. Thus, CK20 mRNA in the peripheral blood from oral SCC patients cannot be a marker for metastatic potentials of the cancer cells, but it can be used as a marker for the evidence of tumour recurrence or the existence of the metastatic tumours after initial treatment. Although the number of samples examined in this experiment is limited at this time, we detected circulating cancer cells in most of the oral cancer-burdened patients, but in none of the tumour-free survivors after treatment. These results suggest that haematogenous cytokeratin 20 mRNA can be a marker for tumour recurrence in oral squamous cell carcinoma patients.
Cytokeratin 20 (Southern blot)   GAPDH   N1  P1  P2  P3  P4  P5  P6  P7  P8  P9  P10  P11 P12 NHt N2 B Figure 3 Amplification of CK20 mRNA from blood samples collected from oral SCC patients by RT-PCR. Total RNA was extracted from 5 ml blood samples from oral SCC patients, and 5 µg of total RNA was subjected to RT-PCR. PCR products were separated on 1.5% agarose gels, and stained with ethidium bromide for GAPDH, or were transferred onto nylon filters and hybridized with digoxigenin-labelled oligonucleotide probe for CK20. P1-P12: oral SCC patients; N1 and N2 healthy volunteers; HNt: oral SCC cells; B: blank (no RNA)
